| __timestamp | BioCryst Pharmaceuticals, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 79529000 |
| Thursday, January 1, 2015 | 13047000 | 91224000 |
| Friday, January 1, 2016 | 11253000 | 102413000 |
| Sunday, January 1, 2017 | 13933000 | 146987000 |
| Monday, January 1, 2018 | 29514000 | 213695000 |
| Tuesday, January 1, 2019 | 37121000 | 342000000 |
| Wednesday, January 1, 2020 | 67929000 | 661000000 |
| Friday, January 1, 2021 | 118818000 | 1283000000 |
| Saturday, January 1, 2022 | 159371000 | 2676000000 |
| Sunday, January 1, 2023 | 213894000 | 3297000000 |
| Monday, January 1, 2024 | 3790000000 |
Unleashing insights
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Genmab A/S and BioCryst Pharmaceuticals, Inc. have demonstrated distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S consistently outpaced BioCryst in SG&A spending, with a staggering 3,297% increase by 2023 compared to BioCryst's 2,139% rise. This trend highlights Genmab's aggressive investment in administrative and sales functions, potentially fueling its growth and market presence. Meanwhile, BioCryst's more conservative spending reflects a different strategic focus. As the biotech industry evolves, these financial decisions will play a pivotal role in shaping each company's future trajectory. Investors and industry analysts should closely monitor these trends to gauge the companies' operational efficiencies and market strategies.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.